EGFR and non-small cell lung carcinoma: The combination of cisplatin, pemetrexed, and bevacizumab was previously reported to be effective in patients with advanced or recurrent nonsquamous NSCLC [15,16,17]; in terms of pathologic response after neoadjuvant therapy, however, the effect may be limited in patients with nonsquamous NSCLC who have EGFR mutations.